Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.62 |
| ▸ | BTK | Q06187 | 9/20 | 0.62 |
| ▸ | ITK | Q08881 | 5/20 | 0.62 |
| ▸ | JAK3 | P52333 | 2/20 | 0.57 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
| ▸ | BLK | P51451 | 1/20 | 0.56 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24150932 | 1.00 | EGFR (0.62) | EGFRBTKITKJAK3FLT3 | |
| SCHEMBL24150531 | 0.89 | JAK3 (0.57) | EGFRBTKITKJAK3 | |
| SCHEMBL30190825 | 0.89 | JAK3 (0.57) | EGFRBTKITKJAK3 | |
| SCHEMBL24150829 | 0.87 | JAK3 (0.55) | EGFRBTKITKJAK3FLT3 | |
| SCHEMBL24150827 | 0.85 | JAK3 (0.53) | EGFRBTKITKJAK3 | |
| SCHEMBL24150523 | 0.84 | JAK3 (0.57) | EGFRBTKITKJAK3BLK | |
| SCHEMBL30190621 | 0.84 | JAK3 (0.52) | EGFRBTKITKJAK3 | |
| SCHEMBL24151398 | 0.84 | JAK3 (0.52) | EGFRBTKITKJAK3 | |
| SCHEMBL24151662 | 0.83 | JAK3 (0.58) | BTKITKJAK3BLK | |
| SCHEMBL24150532 | 0.83 | BTK (0.69) | EGFRBTKITKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | EGFR 888/4885BTK 4194/4885ITK 4359/4885 |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | EGFR 888/4885BTK 4194/4885ITK 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.